Literature DB >> 2511224

Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro.

S J Bhatia1, N Kochar, P Abraham, N G Nair, A P Mehta.   

Abstract

Campylobacter pylori has been implicated as a causative factor in acid-peptic disease. Lactobacillus acidophilus is known to inhibit the growth of pathogens in the human gastrointestinal tract. We recovered C. pylori from gastric antral biopsies of seven patients with acid-peptic disease; the isolates were then cultured in brucella broth. The effect of L. acidophilus (cultured in DeMan-Rogosa-Sharpe broth) on the growth of C. pylori was tested by a mixed culture technique. L. acidophilus inhibited the growth of all seven isolates of C. pylori in vitro. All these isolates were also inhibited by the L. acidophilus culture supernatant (brucella blood agar cup technique) obtained at or after 48 h of incubation. Inhibition of C. pylori growth was also observed with 1 and 3% lactic acid but not with 0.5 and 1% hydrogen peroxide, the L. acidophilus sonic extract, or a citrate-phosphate buffer (pH 4.0). We conclude that the inhibitory action of L. acidophilus on C. pylori is dependent on an extracellular secretory product, probably lactic acid. This inhibitory effect may be of therapeutic relevance in patients with C. pylori-positive acid-peptic disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511224      PMCID: PMC267018          DOI: 10.1128/jcm.27.10.2328-2330.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  TREATMENT OF HEPATIC ENCEPHALOPATHY BY ALTERATION OF INTESTINAL FLORA WITH LACTOBACILLUS ACIDOPHILUS.

Authors:  W A MACBETH; E H KASS; W V MCDERMOTT
Journal:  Lancet       Date:  1965-02-20       Impact factor: 79.321

2.  A Lactobacillus preparation for use with antibiotics.

Authors:  D GORDON; J MACRAE; D M WHEATER
Journal:  Lancet       Date:  1957-05-04       Impact factor: 79.321

3.  Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.

Authors:  B J Marshall; C S Goodwin; J R Warren; R Murray; E D Blincow; S J Blackbourn; M Phillips; T E Waters; C R Sanderson
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

4.  Natural sources and microbiological characteristics of Campylobacter pylori.

Authors:  G F Kasper
Journal:  Scand J Gastroenterol Suppl       Date:  1988

5.  Enterotoxin-producing Escherichia coli and diarrheal disease in adult travelers: a prospective study.

Authors:  E G Shore; A G Dean; K J Holik; B R Davis
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

7.  Campylobacter-like organisms in the stomach of patients and healthy individuals.

Authors: 
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

Review 8.  Role of dietary lactobacilli in gastrointestinal microecology.

Authors:  K M Shahani; A D Ayebo
Journal:  Am J Clin Nutr       Date:  1980-11       Impact factor: 7.045

9.  Production of Hydrogen peroxide by Lactobacillus acidophilus.

Authors:  E B Collins; K Aramaki
Journal:  J Dairy Sci       Date:  1980-03       Impact factor: 4.034

10.  Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment.

Authors:  S L Hazell; W B Hennessy; T J Borody; J Carrick; M Ralston; L Brady; A Lee
Journal:  Am J Gastroenterol       Date:  1987-04       Impact factor: 10.864

View more
  37 in total

1.  Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model.

Authors:  A M Kabir; Y Aiba; A Takagi; S Kamiya; T Miwa; Y Koga
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium.

Authors:  Domitille Fayol-Messaoudi; Cédric N Berger; Marie-Hélène Coconnier-Polter; Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

3.  Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone.

Authors:  J A da Silva Medeiros; T M F O Gonçalves; L Boyanova; M I de Correia Pereira; J N da Silva Paiva de Carvalho; A M de Sousa Pereira; A M Silvério Cabrita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-05       Impact factor: 3.267

4.  PCR detection of colonization by Helicobacter pylori in conventional, euthymic mice based on the 16S ribosomal gene sequence.

Authors:  J G Smith; L Kong; G K Abruzzo; C J Gill; A M Flattery; P M Scott; D Bramhill; C Cioffe; C M Thompson; K Bartizal
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 5.  Probiotics and medical nutrition therapy.

Authors:  Amy C Brown; Ana Valiere
Journal:  Nutr Clin Care       Date:  2004 Apr-Jun

6.  Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB.

Authors:  M H Coconnier; V Lievin; E Hemery; A L Servin
Journal:  Appl Environ Microbiol       Date:  1998-11       Impact factor: 4.792

7.  Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.

Authors:  J Labenz; E Gyenes; G H Rühl; G Börsch
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

Review 8.  Probiotics for the treatment of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; John Frederick Osborn; Enea Bonci; Sara Romaggioli; Rossella Baldini; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 9.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

10.  Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial.

Authors:  David J W Knight; Dale Gardiner; Amanda Banks; Susan E Snape; Vivienne C Weston; Stig Bengmark; Keith J Girling
Journal:  Intensive Care Med       Date:  2008-12-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.